The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ellie Merle - UBS - Analyst
: Awesome. Well, maybe since it's very topical, let's talk about your oral GLP-1. Maybe can you give an overview of TERN-601 and -- yeah, high level,
where you are with that program and next steps?
Question: Ellie Merle - UBS - Analyst
: Exciting. And what are you looking to see in the data?
Question: Ellie Merle - UBS - Analyst
: Awesome. And the GLP-1 landscape is rapidly evolving. Where do you see 601 sitting in this landscape and any points of differentiation?
Question: Ellie Merle - UBS - Analyst
: Awesome. And I know you have an earlier preclinical portfolio, I think, in obesity. Beyond 601, can you tell us a little bit more about what you have
going on in development in your obesity franchise?
Question: Ellie Merle - UBS - Analyst
: Great. Well, certainly looking forward to the obesity data next year. Maybe pivoting to oncology, can you give an overview of TERN-701 and how
allosteric inhibitors like 701 could be differentiated from one another?
Question: Ellie Merle - UBS - Analyst
: And where do you see the unmet need in CML? And what does 701 address that isn't already being addressed with Scemblix?
Question: Ellie Merle - UBS - Analyst
: Maybe what are some of the learnings from asciminib and its clinical development? What was seen there, and some of the learnings from its
commercial experience, and how that informs your clinical development?
Question: Ellie Merle - UBS - Analyst
: Absolutely. And before we go into a little bit more of the clinical design, just from the preclinical data, I guess, what have we learned about the
comparison between 701 and asciminib? And any learnings there?
Question: Ellie Merle - UBS - Analyst
: All right. Great. And I will not ask about the timelines of the Hansoh study. Well, maybe I should because Mark can't talk. Just kidding.
In terms of the Hansoh study, can you provide an overview of the design? You alluded to the fact that it enabled you to start at a higher dose and
will help you enroll in the US. But maybe just provide us an overview of the structure of the design and to the extent that you can, where they are
in that study.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 08, 2023 / 9:30PM, TERN.OQ - Terns Pharmaceuticals Inc at UBS BioPharma Conference
Question: Ellie Merle - UBS - Analyst
: Understood. And can you review the design of your Phase 1 for 701, and in particular, how we should think about timelines for data and what
you're looking to see in that data?
Question: Ellie Merle - UBS - Analyst
: And timelines for data?
Question: Ellie Merle - UBS - Analyst
: Great. Maybe turning to NASH, can you give an overview of TERN-501 and talk about how it could be differentiated from other THR-betas in
development?
Question: Ellie Merle - UBS - Analyst
: And can you go over a little bit in more detail what you saw in the DUET trial, and of course, with the caveats across trial comparison in mind, how
you think the design of the DUET trial compared to other similar Phase 2a trials in the space, as well as the patient population involved?
Question: Ellie Merle - UBS - Analyst
: Absolutely. There's a lot in development for NASH, including GLP-1s, but also other THR-betas. How are you thinking about how 501 fits in the
competitive landscape?
Question: Ellie Merle - UBS - Analyst
: And how should we think about next steps in development and when we could learn more?
Question: Ellie Merle - UBS - Analyst
: Okay. Understood. And just thinking about the NASH landscape broadly, particularly, because you guys also have an oral GLP-1 in development,
how are you thinking about the impact of GLP-1s on the NASH space? And I guess, any plans to explore combinations?
Question: Ellie Merle - UBS - Analyst
:
Question: Ellie Merle - UBS - Analyst
: Maybe taking a step back, you have a handful of programs in clinical development. Strategically, how do you think about potential partnerships?
And is there a framework that you're applying as you think about that?
Question: Ellie Merle - UBS - Analyst
: Absolutely. And maybe just to round it out, a lot of programs ongoing. Remind us of the key milestones over the next 12 months.
Question: Ellie Merle - UBS - Analyst
: That's a great segue. I think we have [Nastech] next. Anyway, thank you, guys, so much for joining us. And looking forward to all the data next year.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 08, 2023 / 9:30PM, TERN.OQ - Terns Pharmaceuticals Inc at UBS BioPharma Conference
| 
